Alle Studien
RekrutierungPHASE3INTERVENTIONELL

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

This study, called ADX-324-302, is for people who have already completed a previous trial for a condition called hereditary angioedema (HAE). HAE is a rare genetic disorder that causes episodes of severe swelling. This new study is an 'extension study,' meaning it follows on from the earlier trial. Its main purpose is to gather more information about how safe the medicine, ADX-324, is over a longer period and how well it helps control swelling attacks in people with Type 1 and Type 2 HAE. Researchers will also look at how the body handles the medicine and how it affects people's quality of life. This study is for adults aged 18 and over who have HAE.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
ADARx Pharmaceuticals, Inc.
Einschreibeziel
90
Starten
02 Apr 2026
Geschätzte Fertigstellung
30 Jun 2030

Worum geht es in dieser Studie?

This study is a follow-up for people who have taken part in a previous clinical trial for hereditary angioedema (HAE). HAE is a conditions where people experience sudden, severe swelling in different parts of their body, which can be painful and sometimes life-threatening. The medicine being studied is called ADX-324.

The main goal of this particular study is to learn more about the long-term effects of ADX-324. While the previous study looked at its initial safety and effectiveness, this extension study will help doctors understand how well the medicine works over a longer time and if it continues to be safe for people with Type 1 and Type 2 HAE.

Researchers will also be checking how the body processes the medication and if it helps improve the daily lives of people living with HAE. This study is an important step in making sure new medicines are both safe and helpful for patients.

Wichtige Erkenntnisse

  • This is an extension study for people with HAE who finished a previous trial.
  • It aims to learn more about the long-term safety and effectiveness of ADX-324 for HAE.
  • Participation involves continued medication and regular health check-ups.
  • The study includes adult participants (18 years and older) with Type 1 or Type 2 HAE.
  • Your well-being and access to acute HAE treatment are important throughout the study.

Wer könnte berechtigt sein?

To join this study, you must have a confirmed diagnosis of hereditary angioedema (HAE), either Type 1 or Type 2. You would also need to have completed the previous study called ADX-324-301. It's also important that you have access to treatments for HAE attacks, such as certain medications that stop the swelling.

There are a few reasons why someone might not be able to join. For example, if you had a bad reaction to the study medicine (ADX-324) in the previous ADX-324-301 study, you wouldn't be able to participate in this extension. The study is open to adults aged 18 and older, both men and women.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Do you have a confirmed diagnosis of hereditary angioedema (HAE) Type 1 or Type 2?
  2. Have you already completed the previous ADX-324-301 study?
  3. Sind Sie 18 Jahre alt oder älter?
  4. Do you have access to treatments for HAE attacks, if needed?
  5. Did you have a negative reaction to the study drug in the previous ADX-324-301 study? (If yes, you might not be eligible).
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to take part, you would continue to receive doses of the study medicine, ADX-324. The study team would closely monitor your health and how you respond to the medicine. This will involve regular visits to the study clinic for assessments, which might include blood tests, physical examinations, and questionnaires about your health and how you are feeling. The exact number and frequency of visits, as well as the total duration you would be involved, would be explained in detail by the study team, as this is an extension study and builds upon previous participation.

Potenzielle Risiken und Vorteile

Taking part in any clinical study has potential benefits and risks. A potential benefit of this study is that you would continue to receive a study medicine that may help manage your HAE. It also contributes to vital research that could help others with HAE in the future. However, there are potential risks, including side effects from the medication, even if it was tolerated in the initial study. The potential side effects, and how they would be managed, will be fully explained to you. Remember, your participation is completely voluntary, and you are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (48)

  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Litchfield Park, United States· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Little Rock, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    San Diego, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Walnut Creek, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Orlando, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Chevy Chase, United States· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Wheaton, United States· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Detroit, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    St. Louis, Vereinigte Staaten· Noch nicht rekrutiert
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Las Vegas, Vereinigte Staaten· Rekrutierung
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten· Rekrutierung
  • ADARx Clinical Site
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten· Noch nicht rekrutiert

Häufige Fragen

What is an 'extension study'?

An extension study is a follow-up study for people who have already taken part in an earlier trial. It helps researchers gather more information about a medicine over a longer period.

What is hereditary angioedema (HAE)?

HAE is a rare genetic condition that causes sudden and repeated episodes of severe swelling in different parts of the body.

What is ADX-324?

ADX-324 is the specific medicine being studied in this trial for its potential to treat hereditary angioedema.

Will I receive treatment for my HAE attacks during the study?

Yes, if you join this study, you must still have access to your usual and approved treatments to manage any HAE attacks you might experience.

Who can participate in this study?

This study is for adults aged 18 and over who have a confirmed diagnosis of Type 1 or Type 2 HAE and have already completed the previous ADX-324-301 study.

Wie Sie mehr erfahren können

Lupe Gallegos

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Phase 3 Extension Study of ADX-324 in Participants With Here… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.